阿尼鲁单抗阻断I型干扰素在系统性红斑狼疮患者中调节关键免疫病理通路:两项3期试验的基因表达与蛋白质组学分析
基于52周随机3期TULIP-1和TULIP-2试验的纵向转录组与蛋白质组分析,评估阿尼鲁单抗对系统性红斑狼疮患者免疫调节机制。与安慰剂相比,阿尼鲁单抗在第24周调节超过2000个基因、第52周调节41种蛋白,下调I型和II型干扰素诱导的基因模块/通路及III型干扰素-λ蛋白水平。
要点
- 阿尼鲁单抗在第24周调节超过2000个基因,第52周结果重叠,并调节41种蛋白。
- 阿尼鲁单抗下调多种I型和II型干扰素诱导的基因模块/通路及III型干扰素-λ蛋白水平。
- 阿尼鲁单抗影响凋亡相关、中性粒细胞胞外诱捕网形成相关转录通路及先天免疫细胞活化趋化因子和受体。
核心结论
- 阿尼鲁单抗阻断I型干扰素可调节I型干扰素信号下游的多条炎症通路,包括在SLE免疫发病机制中起关键作用的凋亡、先天和适应性机制。
研究设计与样本
- 基于52周随机3期TULIP-1和TULIP-2试验,对中重度SLE患者进行纵向转录组和蛋白质组分析。
- 全血RNA测序分析18017个基因(合并TULIP:阿尼鲁单抗n=244,安慰剂n=258)。
- Olink和Simoa面板分析184种血浆蛋白(TULIP-1:阿尼鲁单抗n=124,安慰剂n=132)。
- 患者接受静脉阿尼鲁单抗或安慰剂联合标准治疗。
主要发现
- 与安慰剂相比,阿尼鲁单抗在第24周调节超过2000个基因,第52周结果重叠。
- 与安慰剂相比,阿尼鲁单抗在第52周调节41种蛋白。
- 阿尼鲁单抗下调多种I型和II型干扰素诱导的基因模块/通路及III型干扰素-λ蛋白水平。
- 阿尼鲁单抗影响凋亡相关和中性粒细胞胞外诱捕网形成相关转录通路、先天免疫细胞活化趋化因子和受体、促炎细胞因子及B细胞活化细胞因子。
- RNA-seq计算机解卷积提示阿尼鲁单抗治疗后黏膜相关恒定T细胞和γδT细胞较基线增加,单核细胞减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the immunomodulatory mechanisms of anifrolumab using longitudinal transcriptomic and proteomic analyses of the 52-week, randomised, phase 3 TULIP-1 and TULIP-2 trials. METHODS: Patients with moderate to severe SLE were enrolled in TULIP-1 and TULIP-2 and received intravenous anifrolumab or placebo alongside standard therapy. Whole-blood expression of 18 017 genes using genome-wide RNA sequencing (RNA-seq) (pooled TULIP; anifrolumab, n=244; placebo, n=258) and 184 plasma proteins using Olink and Simoa panels (TULIP-1; anifrolumab, n=124; placebo, n=132) were analysed. We compared treatment groups via gene set enrichment analysis using MetaBase pathway analysis, blood transcriptome modules, in silico deconvolution of RNA-seq and longitudinal linear mixed effect models for gene counts and protein levels. RESULTS: Compared with placebo, anifrolumab modulated >2000 genes by week 24, with overlapping results at week 52, and 41 proteins by week 52. IFNAR1 blockade with anifrolumab downregulated multiple type I and II IFN-induced gene modules/pathways and type III IFN-λ protein levels, and impacted apoptosis-associated and neutrophil extracellular traps-(NET)osis-associated transcriptional pathways, innate cell activating chemokines and receptors, proinflammatory cytokines and B-cell activating cytokines. In silico deconvolution of RNA-seq data indicated an increase from baseline of mucosal-associated invariant and γδT cells and a decrease of monocytes following anifrolumab treatment. DISCUSSION: Type I IFN blockade with anifrolumab modulated multiple inflammatory pathways downstream of type I IFN signalling, including apoptotic, innate and adaptive mechanisms that play key roles in SLE immunopathogenesis.
引用
- Baker T, Sharifian H, Newcombe PJ, et al. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Ann Rheum Dis. 2024. PMID: 38569851. doi:10.1136/ard-2023-225445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。